Wander, Seth A.

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy

Wander, S. A., Hennessy, B. T., & Slingerland, J. M. (2011) · Journal of Clinical Investigation

PI3K/AKT/mTOR signaling in cancerAdvanced Breast Cancer Therapies

Cited by 427

VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer

Hamilton, E. P., Ma, C., De Laurentiis, M., Iwata, H., Hurvitz, S. A., Wander, S. A., Danso, M., Lu, D. R., Perkins Smith, J., Liu, Y., et al. (2024) · Future Oncology

Advanced Breast Cancer TherapiesProtein Degradation and Inhibitors

Cited by 116

TOP1 Mutations and Cross-Resistance to Antibody–Drug Conjugates in Patients with Metastatic Breast Cancer

Abelman, R. O., Wu, B., Barnes, H., Medford, A., Norden, B., Putur, A., Bitman, E., Thant, W., Liu, T., Weipert, C., et al. (2025) · Clinical Cancer Research

Cancer therapeutics and mechanismsLung Cancer Treatments and Mutations

Cited by 61

Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo

Chen, Y., Alvarez, E. A., Azzam, D., Wander, S. A., Guggisberg, N., Jordà, M., Ju, Z., Hennessy, B. T., & Slingerland, J. M. (2011) · Breast Cancer Research and Treatment

Estrogen and related hormone effectsAdvanced Breast Cancer Therapies

Cited by 54